---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-045275"
form_type: "8-K"
ticker: "SER"
cik: "0001708599"
company_name: "Serina Therapeutics, Inc."
filed_at: "2023-12-18T23:59:59+00:00"
generated_at: "2026-06-07T11:21:34.845154+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# AgeX shareholders approve Juvenescence proposal allowing increased stake via preferred conversion

## Summary
- Juvenescence proposal approved: 18,908,391 for, 7,461,795 against, 38,095 abstain; 4.8M broker non-votes.
- Three directors re-elected: Bailey (18.6M for), Hackett (18.9M), Renondin (19.7M); broker non-votes 4.8M each.
- Auditor WithumSmith+Brown ratified: 23.5M for, 7.3M against, 496,875 abstain.
- Meeting held Dec 13, 2023; 82.36% of 37.95M shares represented.

## SEC filing metadata
- accession: 0001493152-23-045275
- form_type: 8-K
- ticker: SER
- cik: 0001708599
- company_name: Serina Therapeutics, Inc.
- filed_at: 2023-12-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708599/000149315223045275/0001493152-23-045275-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708599/000149315223045275/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-045275
- JSON: https://secwatch.observer/filing/0001493152-23-045275.json
- Plain text: https://secwatch.observer/filing/0001493152-23-045275.txt

## Key facts
- Shareholder Votes
  Serina Therapeutics, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accountants at the 2023-12-13 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-12-13
  source text: The appointment of WithumSmith + Brown PC as our independent registered public accountants for the fiscal year ending December 31, 2023 was ratified by the following vote: Shares Voted For 23,460,256 Against 7,298,688 Abstain 496,875
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708599/000149315223045275/0001493152-23-045275-index.htm
- Shareholder Votes
  Serina Therapeutics, Inc. shareholders approved Proposal to permit Juvenescence Limited to acquire additional shares through conversion of Series B Preferred Stock at the 2023-12-13 meeting.
  - Outcome: passed
  - Meeting: 2023-12-13
  source text: The Juvenescence was approved by the following vote: Shares Voted For 18,908,391 Against 7,461,795 Abstain 38,095
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708599/000149315223045275/0001493152-23-045275-index.htm
- Shareholder Votes
  Serina Therapeutics, Inc. shareholders approved Election of three directors at the 2023-12-13 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-12-13
  source text: Each of the following nominees were elected as directors by the following vote: Nominee Votes For Votes Withheld Gregory Bailey 18,629,281 7,779,000 Joanne Hackett 18,946,164 7,462,117 Jean-Christophe Renondin 19,707,041 6,701,172
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708599/000149315223045275/0001493152-23-045275-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.